Tous Actualités
Suivre
Abonner IsoTis OrthoBiologics

IsoTis OrthoBiologics

IsoTis Extends Private Label With AlloSource for First Generation DBM Products US$2.5 Million Payment on Closing

Irvine, California (ots/PRNewswire)

IsoTis, Inc. (NASDAQ: ISOT),
the orthobiologics company, today announced that it has expanded its
existing private label agreement with AlloSource.
AlloSource is IsoTis' primary supply partner and one of the
nation's largest non-profit providers of bone and soft tissue
allografts for use in surgical procedures. Under the agreement
AlloSource receives an exclusive license to use the intellectual
property necessary to manufacture products similar to IsoTis' first
generation DBM products in North America, and a non-exclusive license
to market them to and through AlloSource's own distribution or
private label partners.
IsoTis retains all intellectual property and rights on global
manufacturing and distribution, including the ability to enter into
additional private label agreements. IsoTis will remain the sole
manufacturer for its own first generation products, DynaGraft(R) II &
OrthoBlast(R) II, for the first generation DBM products it currently
manufactures under private label agreements with parties other than
AlloSource, as well as for private label products under potential new
contracts IsoTis may enter into.
IsoTis' Accell family of products (Accell 100, Accell Connexus,
Accell TBM and any new Accell products IsoTis may develop), are not
related to nor affected by the expanded agreement with AlloSource.
IsoTis remains the sole and exclusive manufacturer and market
supplier of Accell products.
The agreement took effect on May 18, 2007. Upon closing, IsoTis
received an upfront payment of US$2.5 million. On the first
Anniversary of the expanded agreement, an additional earnout payment
may be due by AlloSource, based on and depending on first year sales
by AlloSource.
Pieter Wolters, President and CEO of IsoTis said, "We are pleased
to strengthen our relationship with AlloSource, our primary supplier
of tissue and one of our trusted private label partners. The
agreement fits our increased focus on the further development of our
proprietary Accell technology and the commercial rollout of the
Accell products, which represented approximately 70% of our US sales
in the first quarter of 2007. The US$2.5 million upfront payment
gives us additional room to consider the various financing
alternatives for investments in our future growth and current
operations."
About IsoTis, Inc.
IsoTis is a leading orthobiologics company that develops,
manufactures and markets proprietary products for the treatment of
musculoskeletal diseases and disorders. IsoTis' current
orthobiologics products are bone graft substitutes that promote the
regeneration of bone and are used to repair natural, trauma-related
and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is
highlighted by its Accell line of products, which the company
believes represents the next generation in bone graft substitution.
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including those that refer to
management's plans and expectations for future operations, prospects
and financial condition. Words such as "strategy," "expects,"
"plans," "anticipates," "believes," "will," "continues," "estimates,"
"intends," "projects," "goals," "targets" and other words of similar
meaning are intended to identify such forward-looking statements. One
can also identify them by the fact that they do not relate strictly
to historical or current facts. Such statements are based on the
current expectations of the management of IsoTis only. Undue reliance
should not be placed on these statements because, by their nature,
they are subject to known and unknown risks and can be affected by
factors that are beyond the control of IsoTis. Actual results could
differ materially from current expectations due to a number of
factors and uncertainties affecting IsoTis' business, including, but
not limited to, the Company's need to raise additional capital to
continue operations, a competitive sales and marketing environment,
the effects of the Allosource license agreement on the Company's
ongoing operations, the timely commencement and success of IsoTis'
clinical trials and research endeavors, delays in receiving U.S. Food
and Drug Administration or other regulatory approvals (i.e.,. EMEA,
CE), including the risk that the FDA determines that our Accell Putty
and Accell TBM products are not human tissue or class II medical
devices, that the Company is unable to obtain 510(k) clearance for
its Accell products, that the FDA requires the Company to obtain
premarket approval of its Accell products prior to continuing their
marketing, that the FDA requires the Company to produce additional
clinical data to support approval or clearance of its products, that
the FDA imposes compliance measures against the Company for the
marketing of its Accell products, including imposing fines and
injunctions or causing the Company to recall its Accell products,
market acceptance of IsoTis' products, effectiveness of IsoTis'
distribution channels, development of competing therapies and/or
technologies, the terms of any future strategic alliances, the need
for additional capital, the inability to obtain, or meet, conditions
imposed for required governmental and regulatory approvals and
consents. IsoTis expressly disclaims any intent or obligation to
update these forward-looking statements except as required by law.
For a more detailed description of the risk factors and uncertainties
affecting IsoTis, refer to the Annual Report on Form 20-F for the
fiscal year ended December 31, 2006 of IsoTis S.A. (the predecessor
to IsoTis, Inc.), and its other reports filed with the SEC, IsoTis
S.A.'s reports filed from time to time with the Swiss Stock Exchange
(SWX), Euronext Amsterdam N.V., SEDAR at www.sedar.com and the
Toronto Stock Exchange (TSX) and the quarterly report on Form 10-Q
for the quarter ended March 31, 2007 and other reports filed with the
SEC from time to time by IsoTis, Inc.

Contact:

For information contact: Rob Morocco, CFO, +1-949-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-949-855-7195 or +41-21-620-6011, hans.herklots@isotis.com

Plus de actualités: IsoTis OrthoBiologics
Plus de actualités: IsoTis OrthoBiologics
  • 15.05.2007 – 14:21

    IsoTis Reports 2007 First Quarter Results

    Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported results for the first quarter ended March 31, 2007. Revenue Analysis Revenue was US$10.0 million for the first quarter of 2007, representing a 2% increase over revenue of US$9.8 million for the first quarter of 2006. IsoTis' chief distribution channels are its U.S. network of independent distributor ...

  • 09.05.2007 – 14:28

    IsoTis to Release First Quarter 2007 Results on May 15

    Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), a leading orthobiologics company, will release its first quarter 2007 results on May 15 at approximately 4:30 p.m. EST . To discuss these results, the Company will conduct a conference call at 5 p.m. EST / 2:00 p.m. PST/ 11:00 p.m. CET. US Dial In: 1-617-614-6206; UK Dial In +44-20-7365-8426; Continental Europe Dial In: +41-1-800-9569; password: ...

  • 03.05.2007 – 14:16

    IsoTis Receives US Patent Related to Reverse Phase Medium Technology

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that the United States Patent and Trademark Office has awarded US Patent No. 7,205,337, which relates to the company's Reverse Phase Medium (RPM) carrier technology. The patent covers the use of IsoTis' current RPM technology in combination with various demineralized bone matrix (DBM) formulations, such as ...